Search clinical trials for: BI 836880

Total 1209 results

Medtronic Cardiac Rhythm and Heart Failure

Completed

Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications

Heart Failure

China
Brigham and Women's Hospital
Massachusetts General Hospital

Withdrawn

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

Chronic Obstructive Airway Disease

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Daping Hospital and the Research Institute of Surgery...

Unknown

A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure (BIPAP)

Neonatal Respiratory Failure

China
Boehringer Ingelheim

Completed

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Diabetes Mellitus, Type 2

Germany
Biosense Webster, Inc.

Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF (SMARTPULSE PAF)

Drug Refractory Paroxysmal Atrial Fibrillation

United States
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Healthy
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Completed

Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation

Cystic Fibrosis

Australia
Boehringer Ingelheim

Recruiting

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Germany, Spain, Japan, China, United States, Korea, Republic of, Canada, France, Austria, Romania
Boehringer Ingelheim

Recruiting

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Lung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract Cancer

United States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Depressive Disorder, Major

United States
Boehringer Ingelheim

Terminated

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Dermatitis, Atopic

United States, Japan, Canada
Universidade Federal do Rio Grande do Norte

Completed

Non Invasive Ventilation on Peripheral Muscle Function and Aerobic Performance (NIV)

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Obesity

Germany
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Boehringer Ingelheim

Completed

Olmutinib (BI 1482694) ADME Study

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Withdrawn

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States
Boehringer Ingelheim

Terminated

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Neoplasms

United States, Spain, Japan, Netherlands
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Hepatic Insufficiency | Healthy

United States
University of Chicago

Completed

Teaching Use of Respiratory Inhalers (TURI) (TURI)

Asthma | COPD

United States
Albert Einstein College of Medicine

Terminated

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

Sickle Cell Anemia | Acute Chest Syndrome

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Hemorrhage

Belgium
Queen's University
Canadian Institutes of Health Research (CIHR)

Completed

Prevention and Reduction of Obesity Through Active Living (PROACTIVE)

Obesity

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

Asthma in Children

United States
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Not yet recruiting

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Impairment
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Terminated

Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Healthy

Netherlands
Manchester Metropolitan University
Manchester University NHS Foundation Trust

Unknown

Non Invasive Ventilation for Acute Exacerbations in Adult CF (NIVinCF)

Respiratory Failure | Cystic Fibrosis

United Kingdom
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany

3

Subscribe